First patient dosed in Phase 1 trial testing epigenetic restoration approach for progressive age-related vision loss.
The longevity field has spent much of the past decade debating whether aging can be modified at the level of cellular identity itself. Now, one of the sector’s most closely watched theories is taking an important step into the clinic.
Life Biosciences has dosed the first participant in a Phase 1 trial of ER-100, its investigational therapy for optic neuropathies including open-angle glaucoma and NAION. At the platform’s core is controlled expression of three transcription factors – OCT4, SOX2 and KLF4, collectively OSK – aimed at restoring function in retinal ganglion cells that neither regenerate naturally nor respond to existing treatments.
The milestone arrives on a brisk timeline: IND clearance in January, an $80 million Series D closed in April and now, first patient dosed.
Longevity.Technology: The eye has become one of longevity biotech’s more fertile proving grounds; accessible, measurable and biologically unforgiving, it offers a rare place where ambitious rejuvenation hypotheses can be tested against functional endpoints rather than left to circulate indefinitely in the conference-room bloodstream. Life Bio’s first patient dosing is therefore more than an ophthalmology milestone – it is an early clinical encounter between partial epigenetic reprogramming and human disease, with all the promise and peril that implies. The company’s thesis, that controlled OSK expression can restore cellular function by resetting gene expression toward more youthful patterns, sits squarely within one of aging biology’s most tantalizing ideas: that some age-related decline may be less a story of irreversible wreckage than of recoverable biological information. That is a profoundly attractive proposition, not least because medicine has become very good at measuring deterioration and rather less good at reversing it; but this is also where the poetry must meet the protocol. In mice, rejuvenation biology can look enticingly plastic; in humans, the question is whether cellular state can be tweaked with sufficient precision, restraint and repeatability to become a medicine rather than a very clever biological parlor trick.
Testing the information theory
Underpinning ER-100 is an idea that has gained considerable traction in geroscience: that the epigenetic record degrades with age – and that degradation, unlike damage, may be reversible. The epigenetic patterns governing gene expression erode over time; the question Life Bio is now asking, in humans, is whether they can be meaningfully restored.
Dr David Sinclair is a Cofounder of Life Bio
For David Sinclair, cofounder of Life Biosciences and Professor of Genetics at Harvard Medical School, the trial represents an opportunity to begin testing that hypothesis in humans.
“Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.”
The idea has become one of the most discussed concepts in modern geroscience. It has also attracted its share of skepticism. Translating epigenetic reprogramming from laboratory models into safe, controllable therapies has long been regarded as one of the field’s most significant technical challenges.
Why start with the eye?
The choice of indication is not arbitrary. Retinal ganglion cells do not regenerate – damage is permanent, and existing glaucoma treatments address intraocular pressure while the underlying cellular loss continues regardless. NAION has no approved therapies at all. For a platform seeking to demonstrate that epigenetic restoration can do something measurable in humans, the eye is, on balance, a shrewd place to start.
Life Bio’s preclinical data suggested controlled OSK expression could restore visual function in animal models. That was enough to justify the step into humans.
Sharon Rosenzweig-Lipson, Chief Scientific Officer at Life Biosciences, sees the current study as the culmination of years of translational work.
“Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER-100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.”
Sharon Rosenzweig-Lipson is the Chief Scientific Officer at Life Bio Beyond a single indication
Ophthalmology is the entry point, not the destination. Life Bio has been candid about its broader ambitions – epigenetic restoration as a platform technology, with applications across organ systems and age-related conditions that extend well beyond the eye.
That remains contingent on what this trial actually shows. The immediate task is unambiguous: establish safety, demonstrate tolerability and find out whether the biology that looked so promising in animal models has anything to say to human disease.
From theory to evidence
Longevity science has become rich in mechanisms, models and hypotheses. Clinical medicine is rather less interested in elegant theories than in reproducible outcomes. As the first participants move through this study, one of the field’s most ambitious ideas will begin the slow transition from possibility to evidence – and perhaps reveal how much of aging’s biology can truly be rewritten.